Ankeda (bevacizumab biosimilar) / Qilu Pharma 
Welcome,         Profile    Billing    Logout  
 0 Diseases   2 Trials   2 Trials   2 News 
5 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Ankeda (bevacizumab biosimilar) / Qilu Pharma
ChiCTR2000039826: A real world study of the first bevacizumab biological analogue in China (Ankeda) in patients with locally advanced or metastatic non squamous NSCLC

Recruiting
4
600
 
metaphase
The First Affiliated Hospital of Guangxi Medical University; The First Affiliated Hospital of Guangxi Medical University, Guangxi Society of Clinical Oncology
Non-small cell lung cancer
 
 
ChiCTR2000039865: A real world study of the first bevacizumab biological analogue in China (Ankeda) in patients with Colorectal cancer field

Recruiting
4
600
 
Nil
The First Affiliated Hospital of Guangxi Medical University; The First Affiliated Hospital of Guangxi Medical University, Guangxi Society of Clinical Oncology
Colorectal cancer
 
 
BEVTOR, NCT04527068: QL1101 in Combination With JS001 in Patients With pMMR/MSS Refractory Metastatic Colorectal Cancer

Not yet recruiting
2
50
RoW
Bevacizumab, QL1101, Tripleitriumab, JS001
Second Affiliated Hospital, School of Medicine, Zhejiang University, Qilu Pharmaceutical Co., Ltd., Shanghai Junshi Bioscience Co., Ltd.
Refractory Metastatic Colorectal Cancer, pMMR, MSS
09/21
02/22
NCT05585281: A Study of Fluzoparib Combined With QL1101 Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy

Recruiting
2
25
RoW
Fluzoparib, QL1101
Yongpeng Wang
Ovarian Cancer
11/25
12/25
NCT06232902: A Study to Compare the Pharmacokinetics and Safety of QL1101 and EU-Avastin® in Healthy Volunteers

Completed
1
84
RoW
QL1101, Avastin®
Qilu Pharmaceutical Co., Ltd.
Tumor
11/24
11/24

Download Options